Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAbrdn Di&g Regulatory News (ADIG)

  • This share is currently suspended. It was suspended at a price of 13.33

Share Price Information for Abrdn Di&g (ADIG)

Share Price is delayed by 15 minutes
Get Live Data
13.33    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: £40.16m
ADIG Live PriceLast checked at - London Stock Exchange

Intraday Abrdn Di&g Share Chart

Update on Managed Wind-Down

11 Mar 2026 07:00

RNS Number : 1273W
abrdn Diversified Income and Growth
11 March 2026
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED ("UK MAR"). ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THE JURISDICTION.

11 March 2026

For Immediate Release

ABRDN DIVERSIFIED INCOME AND GROWTH PLC

(the "Company")

 

Update on Managed Wind-Down

The Board is pleased to announce that the Company has completed two further secondary sales of its fund investments and private market assets ("Fund Interests") (the "Newly Completed Sales") raising gross consideration of approximately £13.8 million. In addition, the Company has entered into further conditional sale and purchase agreements in respect of an additional Fund Interest (the "Newly Agreed Sale") for gross consideration of approximately £13.3 million (subject to customary completion adjustments and before transaction costs).

As previously reported, each of the Fund Interests sold pursuant to the Newly Completed Sales were being carried by the Company at the agreed sale price in the Company's last reported net asset value ("NAV") (as at 31 December 2025), which also included accruals for the Company's expected transaction, operating and liquidation costs. Furthermore, in the light of the advanced stage of negotiations, the Fund Interest to be sold pursuant to the Newly Agreed Sale was also being carried by the Company at the agreed sale price in the 31 December 2025 NAV.

These recent developments leave only the Fund Interest that is the subject of the Newly Agreed Sale and the remaining 50 per cent. of an additional Fund Interest subject to the Company's secondary sales process (together, the "Remaining Sales").(1) Both of the Remaining Sales are now subject to signed conditional sale agreements. The completion of the Remaining Sales remains subject to certain conditions but are currently expected to complete during the week commencing 16 March 2026. Accordingly, the Board expects to write to shareholders of the Company shortly regarding proposals to place the Company into members' voluntary liquidation. 

The timing of receipt of consideration from the Remaining Sales will be driven by the closing date of the transaction.

Enquiries:

abrdn Diversified Income and Growth plc

Davina Walter (Chairman) via Burson Buchanan

Dickson Minto Advisers LLP

Douglas Armstrong / Andrew Clark / Jamie Seedhouse +44 (0)20 7649 6823

Burson Buchanan

Helen Tarbet / Henry Wilson / Nick Croysdill +44 (0)20 7466 5000

ADIG@buchanancomms.co.uk

Notes:

(1) The Company's interests in Aberdeen Global Private Markets Fund (which was exited through the fund's redemption mechanics in September 2025) and PIMCO Private Income Fund (which is expected to be exited through the fund's redemption mechanics in Q4 2026) were excluded from the Company's secondary sales process. The Company's residual interests in Markel Catco Reinsurance Opportunities Fund (a de minimis holding in a fund in managed wind-down) and Aberdeen European Residential Opportunities Fund (the value of which was written down to nil on 31 January 2025) were also excluded from the Secondary Sales Process.

Important information

This announcement is released by the Company and the information contained within this announcement is deemed by the Company to constitute inside information for the purposes of Article 7 of UK MAR. Upon publication of this announcement via a Regulatory Information Service, such information is now considered to be in the public domain. The person responsible for arranging for the release of this announcement on behalf of the Company is abrdn Holdings Limited, the Company Secretary.

The Company's LEI number is 2138003QINEGCHYGW702.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDBGDXSGBDGLG
Date   Source Headline
3rd Sep 202512:35 pmRNSNet Asset Value(s)
2nd Sep 202511:33 amRNSNet Asset Value(s)
1st Sep 20253:01 pmRNSHolding(s) in Company
29th Aug 202512:29 pmRNSNet Asset Value(s)
28th Aug 20252:12 pmRNSHolding(s) in Company
28th Aug 202511:31 amRNSNet Asset Value(s)
27th Aug 202512:58 pmRNSNet Asset Value(s)
26th Aug 202511:15 amRNSNet Asset Value(s)
22nd Aug 202512:31 pmRNSNet Asset Value(s)
21st Aug 202511:58 amRNSNet Asset Value(s)
20th Aug 202512:25 pmRNSNet Asset Value(s)
19th Aug 202512:26 pmRNSNet Asset Value(s)
18th Aug 202511:22 amRNSNet Asset Value(s)
15th Aug 202511:50 amRNSNet Asset Value(s)
14th Aug 202511:26 amRNSNet Asset Value(s)
13th Aug 202512:07 pmRNSNet Asset Value(s)
12th Aug 202511:46 amRNSNet Asset Value(s)
11th Aug 202512:27 pmRNSNet Asset Value(s)
8th Aug 202511:25 amRNSNet Asset Value(s)
7th Aug 202511:25 amRNSNet Asset Value(s)
6th Aug 202512:28 pmRNSNet Asset Value(s)
5th Aug 20255:05 pmRNSMonth End Net Asset Value(s)
5th Aug 202512:25 pmRNSNet Asset Value(s)
4th Aug 202512:29 pmRNSNet Asset Value(s)
1st Aug 202510:52 amRNSHolding(s) in Company
31st Jul 202512:38 pmRNSNet Asset Value(s)
30th Jul 202511:26 amRNSNet Asset Value(s)
29th Jul 202511:52 amRNSNet Asset Value(s)
28th Jul 20251:45 pmRNSNet Asset Value(s)
25th Jul 202511:36 amRNSNet Asset Value(s)
24th Jul 202510:21 amRNSNet Asset Value(s)
23rd Jul 202511:32 amRNSNet Asset Value(s)
22nd Jul 202510:59 amRNSNet Asset Value(s)
21st Jul 202510:57 amRNSNet Asset Value(s)
18th Jul 202510:38 amRNSNet Asset Value(s)
17th Jul 202512:17 pmRNSNet Asset Value(s)
16th Jul 202512:39 pmRNSNet Asset Value(s)
15th Jul 202511:37 amRNSNet Asset Value(s)
14th Jul 202512:30 pmRNSNet Asset Value(s)
11th Jul 202511:57 amRNSNet Asset Value(s)
10th Jul 202511:44 amRNSNet Asset Value(s)
9th Jul 202512:15 pmRNSNet Asset Value(s)
8th Jul 202511:09 amRNSNet Asset Value(s)
7th Jul 202512:00 pmRNSNet Asset Value(s)
4th Jul 202511:32 amRNSNet Asset Value(s)
4th Jul 202511:11 amRNSMonth End Net Asset Value(s)
3rd Jul 202512:33 pmRNSNet Asset Value(s)
2nd Jul 20255:00 pmRNSQuarterly Disclosures
2nd Jul 20251:39 pmRNSNet Asset Value(s)
30th Jun 202512:21 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.